NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent
July 08 2014 - 12:05AM
Business Wire
Supplies Product to NASA, Working with U.S.
Representative Tim Ryan on Potential for Federal Contracts
NanoLogix, Inc. (OTCBB:NNLX), an innovator in the rapid
detection of viable bacteria, and identification and determination
of antibiotic resistance/sensitivity of those bacteria, announces
that it is exhibiting at the BioOhio BioScience Expo and Showcase
to be held in Aurora, Ohio on August 5th at the Bertram Conference
Center. Sebastian Faro MD., PhD, a highly recognized authority on
infectious diseases of female reproductive systems, will be
presenting on the NanoLogix N-Assay Multiwell Microplate Assay
during the event. NanoLogix is also a sponsor of the Expo. There is
no charge for admission. Further information is available by
following this link:
Patented FlatPack packaging for Petri
products, exclusively licensed to NanoLogix Incorporated (Photo:
Business Wire)
http://www.bioohio.com/events/expo/
European Patent
The European Patent Office has informed our London and US Patent
Law firms that our European application for the NanoLogix BNP
sandwiched-membrane Petri based detection technology has received
an allowance for grant under the European Patent Convention. The
patent will cover up to 38 member countries, dependent upon
NanoLogix’s election, and significantly enhances the NanoLogix
Patent Portfolio. The BNP technology received patent grants in 2013
in both Japan and Russia and is currently patent pending in the
United States.
NASA
At the American Society for Microbiology (ASM) annual meeting in
late May, NanoLogix’s display booth was visited by NASA. Upon
viewing the NanoLogix Petri plates vacuum packed in
nitrogen-charged FlatPacks, the following comment was made by a
NASA scientist: “This is exactly what we’ve been looking for.
We’re sending these up there,” referring to the International Space
Station (ISS).
In early June, at NASA’s request, NanoLogix supplied NASA with a
number of Petri and BNP FlatPacks for their use. The company is
currently awaiting further information from NASA and will release
additional news as appropriate. The qualities that are of interest
to NASA are the robust nature of the Petri dishes packaged in the
patented FlatPack with enhanced durability and resistance to
breakage, coupled with the long term room-temperature shelf life of
at least two years, compared to the competition’s shelf life of
3-1/2 months refrigerated.
Congressional Assistance
NanoLogix is pleased to announce that it is receiving assistance
from Tim Ryan, U.S. Representative for Ohio’s 13th Congressional
District and his staff in exploring potential Federal government
uses for its technologies. NanoLogix management will be traveling
to Washington DC in July for meetings with the Congressman and his
staff.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical, National
Defense, and homeland security applications, NanoLogix technology
is applicable in pharmaceutical, industrial, veterinary and
environmental testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity.
For more information visit: http://www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140707006058/en/
NanoLogix, Inc.Carol Surrena, 330-534-0800info@nanologix.com
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Nov 2024 to Dec 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Dec 2023 to Dec 2024